Why Most Reach-Through Royalty Claims Poison University-Industry Deals Before They Close

Reach-through royalties sound defensible on paper. A university licenses a research tool or platform technology, and the license includes a provision claiming a percentage of any product revenues that result from using that tool downstream. The logic seems fair: if our technology helped you build a $500 million drug, we deserve a slice.

The problem is that this logic collapses almost immediately when it meets real deal-making.

Here's what actually happens. A biotech company negotiates a license for a university's screening platform or gene-editing tool. Their legal team spots the reach-through clause. Maybe it's 1-3% of net sales on any product developed using the licensed technology. The biotech's CFO runs the numbers on a successful drug launch and sees an obligation that could dwarf the entire value of the original license. Suddenly the deal slows. Lawyers start exchanging lengthy position papers. The corporate development team quietly begins scoping out alternative tools or workarounds.

Some deals die outright. Others get renegotiated so heavily that the university ends up with less than a clean upfront fee would have delivered.

What makes reach-through provisions especially corrosive is their ambiguity. Define "developed using" with any precision and you'll spend months doing it. Did the company use the tool for one screening campaign in year two of a ten-year development program? Does that create a reach-through obligation on the final product? Most license agreements leave this genuinely unclear, which means both parties are signing a document they interpret differently.

The biotech assumes the clause is narrow and unlikely to apply. The technology transfer office assumes it's broad and will generate real revenue. Neither assumption gets tested until a product succeeds, at which point the relationship has usually evolved into something adversarial.

There's also a portfolio problem. Biotech companies license dozens of tools and platform technologies over the course of a development program. If multiple licenses carry reach-through provisions, the stacking effect becomes genuinely unworkable. A company cannot responsibly model its economics when an unknowable fraction of future product revenues is pre-committed to a collection of research tool providers. Investors notice this. Term sheets get complicated. Some rounds don't close.

Why do technology transfer offices keep including these provisions? Partly inertia: reach-through language has been in template agreements for decades, originating from an era when universities had fewer licensing options and wanted to participate in commercial upside. Partly genuine belief that the language is negotiable and signals a starting position. And partly because TTO staff get evaluated on deal terms rather than deal outcomes, which creates pressure to include provisions that look strong on paper.

But "looks strong on paper" and "generates revenue" are not the same thing.

Better alternatives exist and experienced licensing officers know them. A higher upfront license fee captures value immediately without creating downstream uncertainty. Milestone payments tied to specific development events (IND filing, Phase II initiation, first commercial sale) align incentives without the definitional chaos of reach-through claims. A modest running royalty on the tool itself, rather than on downstream products, preserves university participation in commercial success without terrifying the company's financial modelers.

For genuinely platform-level contributions where the university IP is central to multiple product opportunities, an equity position in the spinout or licensing company often delivers better returns than any royalty structure. Equity appreciates with the company's success rather than triggering per-product accounting disputes.

graph TD
    A[Research Tool Licensed] --> B{Reach-Through Clause?}
    B -->|Yes| C(Ambiguity Over Scope)
    C --> D[Deal Slows or Collapses]
    B -->|No| E(Clean Fee + Milestones)
    E --> F[Deal Closes Faster]
    F --> G((Actual Revenue Realized))

The diagram oversimplifies, but the directional truth holds. Provisions that generate ambiguity generate friction. Friction kills deals. Killed deals generate zero revenue, which is worse than any royalty percentage you could have negotiated.

Technology transfer professionals who push back on reach-through language aren't giving away the store. They're making a pragmatic calculation: a deal that closes with clean terms at a fair upfront fee plus structured milestones outperforms a deal that stalls for eighteen months and then fails, or that closes with language both sides interpret differently and will fight about in five years.

Universities that have modernized their research tool licensing agreements consistently report faster deal cycles, higher licensee satisfaction, and counterintuitively, better total revenue outcomes. The mechanism isn't mysterious: companies that trust the licensing relationship bring more opportunities back to the same university.

Reputation compounds. So does deal velocity. Reach-through provisions, whatever their theoretical appeal, tend to corrode both.